The Globe and Mail featured a new study published Thursday in the Lancet, which concludes that the overall risks of statins, which are designed to lower cholesterol, are small. But debate continues whether the risks are worth it.
UBC pharmaceutical sciences professor James McCormack was quoted as saying that the debate has become too heated. It would be better to simply present the pros and cons to patients and let them decide, in consultation with their health-care provider.
